Experience Greater Freedom From HAE With HAEGARDA Running Tennis Woman Shards of Glass
Experience Greater Freedom From HAE With HAEGARDA Running Tennis Woman Shards of Glass
WITH THE only subcutaneous INJECTION FOR THE PREVENTION OF HAE ATTACKS

HAEGARDA REDUCED HAE ATTACKS BY 95%*†

Woman standing
Reduction in HAE attacks with HAEGARDA 60 IU/kg vs placebo (median)
Overall reduction in HAE attacks per month relative to placebo
haegarda95_bubble 95

The mean reduction in number of HAE attacks per month with HAEGARDA 60 IU/kg vs placebo was 84%: 0.5 (95% ci 0.0–1.0) vs 4.0 (95% ci 3.5–4.6), respectively; P<0.001.

The mean reduction in number of HAE attacks per month with HAEGARDA 60 IU/kg vs placebo was 84%: 0.5 (95% CI 0.0–1.0) vs 4.0 (95% CI 3.5–4.6), respectively; P<0.001.

Number of uses of rescue medication per month relative to placebo

  • >99% less rescue medication with HAEGARDA 60 IU/kg vs placebo (median)‡1
The image explains how the use of rescue medication was reduced to zero for the patients treated with HAEGARDA for preventing hereditary angioedema (HAE) attacks.

*Median reduction vs placebo.
In a 32-week crossover study, patients ≥12 years of age with symptomatic type 1 or 2 HAE (N=90) were randomly assigned to twice-weekly treatment with HAEGARDA 40 IU/kg or 60 IU/kg. Patients initiated 16 weeks of active treatment or placebo and crossed over to placebo or active treatment for the subsequent 16 weeks. Baseline HAE attack frequency was 8.8 in the 3 months before screening for the 60 IU/kg group.1
The WAO Guideline for the Management of HAE states that patients should have HAE rescue medication available at all times.2

HAEGARDA REPLACES MISSING OR DYSFUNCTIONAL C1-INH, RESTORING C1-INH LEVELS ABOVE 40%

Subcutaneous C1-INH builds and maintains steady-state C1-INH functional activity*3

Subcutaneous HAEGARDA 6000 IU3

C1_INH_functional_chart

Steady state is expected within 3 to 4 doses1

* The plasma levels of C1-INH functional activity were evaluated in patients with type 1 or type 2 HAE in a Phase 3, placebo-controlled, crossover study. Patients received twice-weekly subcutaneous injections of HAEGARDA 40 IU/kg or 60 IU/kg for 16 weeks. The model-derived outcome is the steady-state C1-INH functional activity vs time.3

HAEGARDA SAFETY AND TOLERABILITY

Adverse reactions occurring in >4% of patients while taking HAEGARDA

Adverse Reaction HAEGARDA
(n=86)
Placebo
(n=86)
Injection-site reaction* 27 (31%) 21 (24%)
Nasopharyngitis 9 (11%) 6 (7%)
Hypersensitivity 5 (6%) 1 (1%)
Dizziness 4 (5%) 1 (1%)

*Includes bruising, coldness, discharge, erythema, hematoma, hemorrhage, induration, edema, pain, pruritus, rash, injection-site reaction, scarring, swelling, urticaria, and warmth at the injection site.
Includes hypersensitivity, pruritus, rash, and urticaria.
Includes patients who were treated with 40 IU/kg and 60 IU/kg.

Injection-site reactions were the most commonly reported adverse reactions

  • 95% of injection-site reactions were of mild intensity
  • 83% of injection-site reactions resolved within 24 hours
  • No injection-site reactions were serious or led to discontinuation of treatment1
  • 1 patient discontinued HAEGARDA because of a treatment-related adverse reaction (urticaria)1

NO THROMBOEMBOLIC EVENTS with HAEGARDA in clinical trials

Standing tennis women Standing tennis women

INDIVIDUALIZED APPROACH THROUGH WEIGHT-BASED DOSING

Dosing is calculated by weight

  • Each patient receives an individualized amount of HAEGARDA specific to his/her body weight
  • No dosage adjustment is needed for adolescents (≥12 years of age) or elderly patients (≥65 years of age)

Dosing Examples: HAEGARDA 60 IU/kg

Patient Weight HAEGARDA Dosage Injection Volume
75 lb (34 kg) 2040 IU 4.1 mL
100 lb (45 kg) 2700 IU 5.4 mL
150 lb (68 kg) 4080 IU 8.2 mL
175 lb (80 kg) 4800 IU 9.6 mL

Patients can self-administer at home or on the go

  • HAEGARDA does not require refrigeration
  • HAEGARDA can be administered in any applicable subcutaneous injection site
  • HAEGARDA is supplied in a kit containing 1 single-use vial of 2000 IU or 3000 IU lyophilized powder with 4 mL or 6 mL Sterile Water for Injection, USP
  • HAEGARDA nurses are there from the very first day to teach self-administration skills
HAEGARDA connect

Welcome to HAEGARDA ConnectSM

HAEGARDA Connect provides patient support from 8AM to 8PM ET. 1-844-HAEGARDA (1-844-423-4273)

When enrolled, patients will be introduced to a range of programs, such as:

hands forming a heart

Financial assistance

Co-pay assistance for commercially insured patients

nurse

The bridge program

A temporary assistance program for those who experience a gap or change in insurance coverage

advocates

Patient assistance

Patient assistance for people who do not have coverage

For more information about HAEGARDA Connect, visit the Patient Website

You are now leaving the current website.

Do you want to continue?